JP2023506805A5 - - Google Patents

Info

Publication number
JP2023506805A5
JP2023506805A5 JP2022535918A JP2022535918A JP2023506805A5 JP 2023506805 A5 JP2023506805 A5 JP 2023506805A5 JP 2022535918 A JP2022535918 A JP 2022535918A JP 2022535918 A JP2022535918 A JP 2022535918A JP 2023506805 A5 JP2023506805 A5 JP 2023506805A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022535918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506805A (ja
JP7827624B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/136396 external-priority patent/WO2021121204A1/zh
Publication of JP2023506805A publication Critical patent/JP2023506805A/ja
Publication of JP2023506805A5 publication Critical patent/JP2023506805A5/ja
Application granted granted Critical
Publication of JP7827624B2 publication Critical patent/JP7827624B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022535918A 2019-12-16 2020-12-15 抗cea抗体-エキサテカン類似体複合体及びその医薬用途 Active JP7827624B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911294912.3 2019-12-16
CN201911294912 2019-12-16
PCT/CN2020/136396 WO2021121204A1 (zh) 2019-12-16 2020-12-15 抗cea抗体-依喜替康类似物偶联物及其医药用途

Publications (3)

Publication Number Publication Date
JP2023506805A JP2023506805A (ja) 2023-02-20
JP2023506805A5 true JP2023506805A5 (cg-RX-API-DMAC7.html) 2023-12-20
JP7827624B2 JP7827624B2 (ja) 2026-03-10

Family

ID=76478217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535918A Active JP7827624B2 (ja) 2019-12-16 2020-12-15 抗cea抗体-エキサテカン類似体複合体及びその医薬用途

Country Status (13)

Country Link
US (1) US20230055408A1 (cg-RX-API-DMAC7.html)
EP (1) EP4079761A4 (cg-RX-API-DMAC7.html)
JP (1) JP7827624B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220113747A (cg-RX-API-DMAC7.html)
CN (2) CN118453897A (cg-RX-API-DMAC7.html)
AU (1) AU2020410460A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011632A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163130A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007312A (cg-RX-API-DMAC7.html)
MY (1) MY209735A (cg-RX-API-DMAC7.html)
TW (1) TWI887316B (cg-RX-API-DMAC7.html)
UA (1) UA129521C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021121204A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230101735A1 (en) * 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン,インコーポレイテッド 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用
EP4489862A1 (en) * 2022-03-09 2025-01-15 Merck Patent GmbH Anti-ceacam5 antibodies and conjugates and uses thereof
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
KR20260115642A (ko) 2023-11-20 2026-07-24 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 재조합 반응을 통해 이종다량체를 제조하는 방법
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2026158363A1 (zh) * 2025-01-22 2026-07-30 石药集团巨石生物制药有限公司 抗体-药物偶联物及其用途
CN120504738B (zh) * 2025-07-21 2025-10-21 南京滴力生物科技有限公司 一种抗δ样配体3的单克隆抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1558284B1 (en) * 2002-10-08 2013-09-11 Immunomedics, Inc. Combination therapy with naked class iii anti-cea monoclonal antibodies and therapeutic agents
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CN102850400A (zh) * 2011-06-30 2013-01-02 周文强 喜树碱衍生物及其制备方法、药物组合物与用途
CN104168899B (zh) 2012-01-13 2017-04-05 通用医疗公司 麻醉剂化合物及其相关的使用方法
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
CN107753954A (zh) * 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
FR3008408B1 (fr) * 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
JP6427789B2 (ja) * 2013-07-23 2018-11-28 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. Cl2aリンカーを有する抗体−sn−38免疫複合体
EP3066470A4 (en) * 2013-11-05 2017-05-31 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
KR20190133233A (ko) * 2017-03-30 2019-12-02 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항체-약물 접합체를 제조하는 방법
CA3044082A1 (en) * 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
TW202115125A (zh) * 2019-06-26 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 抗cea抗體及其應用

Similar Documents

Publication Publication Date Title
JP2023510905A5 (cg-RX-API-DMAC7.html)
JP2023505708A5 (cg-RX-API-DMAC7.html)
JP2022511351A5 (cg-RX-API-DMAC7.html)
JP2023519261A5 (cg-RX-API-DMAC7.html)
TWI904149B (zh) B7h3抗體-依喜替康類似物偶聯物及其醫藥用途
TWI796245B (zh) 抗體-藥物結合物之用途
JP6914956B2 (ja) 抗5t4抗体および抗体−薬物コンジュゲート
EP3678700B1 (en) Compounds for reducing the viscosity of biological formulations
JP7827624B2 (ja) 抗cea抗体-エキサテカン類似体複合体及びその医薬用途
EP3186278A1 (en) Internalizing moieties for treatment of cancer
CN116096896A (zh) 一种含抗体药物偶联物的药物组合物及其用途
JP2024536798A5 (cg-RX-API-DMAC7.html)
RU2022125170A (ru) Конъюгат антитела против PSMA и аналога эксатекана и его медицинское применение
JP2023500385A5 (cg-RX-API-DMAC7.html)
RU2021110631A (ru) Конъюгат лиганд-лекарственное средство аналога экзатекана, способ его получения и его применение
TH2101001650A (th) ลิแกนด์-ดรักคอนจูเกตของสารแอนะล็อกของเอกซาทีแคน, วิธีการเตรียมสำหรับคอนจูเกตนั้น และการประยุกต์ใช้คอนจูเกตดังกล่าว
JP2025540696A (ja) 抗cldn18.2抗体薬物複合体、その医薬組成物及び使用
RU2021110824A (ru) Конъюгат антитело к b7h3-аналог экзатекана и его применение в медицине
RU2025102276A (ru) КОНЪЮГАТ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩИЙ МУТАНТНУЮ Fc-ОБЛАСТЬ
RU2021135114A (ru) Конъюгат антитела к b7-h4 и лекарственного средства и его медицинское применение
WO2025232682A1 (zh) 海兔毒素类似物及其配体偶联药物及其制备方法与应用
RU2025110275A (ru) Лекарственное средство на основе ауристатина с высокостабильным гидрофильным линкерным элементом и его конъюгат
RU2022110139A (ru) Производное каптотецина и его конъюгат
IL324844A (en) Nectin-4 antibodies and antibody-drug conjugates
RU2024116437A (ru) Конъюгат антитело-лекарственное средство и его применение